Ossowski Stephanie, Hung Yun-Yi, Banks Kian, Hsu Diana, Herrinton Lisa, Ashiku Simon, Patel Ashish, Suga J Marie, Velotta Jeffrey B
Department of Hematology/Oncology, Kaiser San Francisco Medical Center, San Francisco, CA, USA.
Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
J Thorac Dis. 2022 Sep;14(9):3352-3363. doi: 10.21037/jtd-22-427.
Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor that should be managed by an experienced surgical and multidisciplinary group. Our objective was to determine the impact of proficient surgeons and MPM bi-disciplinary review on outcomes of patients with MPM.
Through this cohort study, electronic medical records of 368 adult patients with MPM from 1/1/2009 to 12/31/2020 were reviewed and compared before and after MPM surgeries were regionalized to specialized surgeons and bi-disciplinary review of MPM patient treatment options. We used the Kaplan-Meier method and log-rank tests to compare survival rates by period, by treatment type, and by stage. Patients were followed from cancer diagnosis date until they died or end of study follow-up, whichever occurred first. We also conducted Cox proportional hazards regression model to examine the overall survival (OS) with adjustments for age, histology, stage, and Charlson comorbidity index (CCI).
Despite similar staging, more patients received any MPM directed treatment from 2015-2020 compared with those patients from 2009-2014. Specifically, there was an increase in patients who received pleurectomy/decortication (PD) from 2015-2020 compared to those who received PD in 2009-2014. Patients with similar age, CCI, stage, and histology had an increase in OS of 12 months with multimodality therapy (surgery, systemic therapy, +/- radiation) compared to those patients who received no treatment.
Consolidating mesothelioma surgery to a specialized surgical team and regular bi-disciplinary review of MPM cases to determine appropriate multimodality therapy, increases the incorporation of surgical treatments in the management of patients with MPM.
恶性胸膜间皮瘤(MPM)是一种罕见且侵袭性强的肿瘤,应由经验丰富的外科和多学科团队进行管理。我们的目标是确定熟练的外科医生和MPM双学科评估对MPM患者治疗结果的影响。
通过这项队列研究,回顾并比较了2009年1月1日至2020年12月31日期间368例成年MPM患者的电子病历,这些病历来自MPM手术区域化至专业外科医生以及对MPM患者治疗方案进行双学科评估之前和之后。我们使用Kaplan-Meier方法和对数秩检验,按时期、治疗类型和分期比较生存率。从癌症诊断日期开始对患者进行随访,直至患者死亡或研究随访结束,以先发生者为准。我们还进行了Cox比例风险回归模型,以在调整年龄、组织学、分期和Charlson合并症指数(CCI)的情况下检查总生存期(OS)。
尽管分期相似,但与2009 - 2014年的患者相比,2015 - 2020年有更多患者接受了任何MPM定向治疗。具体而言,与2009 - 2014年接受胸膜切除术/去皮质术(PD)的患者相比,2015 - 2020年接受PD的患者有所增加。年龄、CCI、分期和组织学相似的患者,与未接受治疗的患者相比,多模式治疗(手术、全身治疗、+/-放疗)使OS增加了12个月。
将间皮瘤手术整合到专业手术团队,并定期对MPM病例进行双学科评估以确定合适的多模式治疗,可增加手术治疗在MPM患者管理中的应用。